Overview

EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)

Status:
NOT_YET_RECRUITING

Trial end date:
2030-09-30

Target enrollment:

Participant gender:

Summary

This study is designed to demonstrate the efficacy and assess safety and tolerability of oral daily alpelisib in participants with PIK3CA-related overgrowth spectrum (PROS).

Phase:

PHASE2

Details

Lead Sponsor:

Novartis Pharmaceuticals

Treatments:

Alpelisib